[New medical approaches to disability].
Pellegrini
Nadine
N
Service de réanimation, Centre de référence maladies neuromusculaires, CIC-IT 805-Innovations et handicap moteur-(Inserm), hôpital Raymond-Poincaré (AP-HP), Garches.
Annane
Djillali
D
D019274:Botulinum Toxins, Type A / Q000627:therapeutic use*; D006233:Persons with Disabilities; D056947:Enzyme Replacement Therapy; D005087:Glucan 1,4-alpha-Glucosidase / Q000627:therapeutic use*; D006801:Humans; D016756:Immunoglobulins, Intravenous; D009422:Nervous System Diseases / Q000188:drug therapy*; D009465:Neuromuscular Agents / Q000627:therapeutic use*
D016756:Immunoglobulins, Intravenous; D009465:Neuromuscular Agents; D005087:Glucan 1,4-alpha-Glucosidase; D019274:Botulinum Toxins, Type A